SCHEMBL29472159

SCHEMBL29472159

CC(=O)N[C@@H]1[C@@H](O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H](CO)O[C@H]1O

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.59
▸ LGALS3 P17931 5/20 0.49
▸ LGALS8 O00214 1/20 0.49
▸ LGALS4 P56470 1/20 0.49
▸ BDNF P23560 3/20 0.45
▸ PTN P21246 2/20 0.45
▸ MDK P21741 2/20 0.45
▸ CD69 Q07108 1/20 0.44
▸ NOD2 Q9HC29 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ THRB P10828 1/20 0.43
▸ CHIA Q9BZP6 1/20 0.40
▸ LGALS1 P09382 1/20 0.39
▸ LGALS7; LGALS7B P47929 1/20 0.39
▸ FGF1 P05230 1/20 0.39
▸ FGF2 P09038 1/20 0.39
▸ VEGFA P15692 1/20 0.39
▸ HPSE Q9Y251 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19864355 1.00 MAPK1 (0.59) MAPK1LGALS3LGALS8LGALS4BDNF
SCHEMBL29533003 1.00 MAPK1 (0.59) MAPK1LGALS3LGALS8LGALS4BDNF
SCHEMBL8062325 1.00 MAPK1 (0.59) MAPK1LGALS3LGALS8LGALS4BDNF
SCHEMBL12878533 1.00 MAPK1 (0.59) MAPK1LGALS3LGALS8LGALS4BDNF
SCHEMBL30055691 1.00 MAPK1 (0.59) MAPK1LGALS3LGALS8LGALS4BDNF
SCHEMBL24484198 0.94 MDK (0.53) MAPK1LGALS3LGALS8LGALS4BDNF
SCHEMBL6748051 0.94 MDK (0.53) MAPK1LGALS3LGALS8LGALS4BDNF
SCHEMBL22071113 0.94 MDK (0.53) MAPK1LGALS3LGALS8LGALS4BDNF
SCHEMBL20516492 0.94 MDK (0.53) MAPK1LGALS3LGALS8LGALS4BDNF
SCHEMBL31067693 0.94 MDK (0.53) MAPK1LGALS3LGALS8LGALS4BDNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260043803-A1 MEANS FOR DETECTING SCHISTOSOMA INFECTION ACADEMISCH ZIEKENHUIS LEIDEN (NL) 2026-02-12 — — US disclosed
US-12410461-B2 Method of preparing clinical samples for nucleic acid amplification DAY ZERO DIAGNOSTICS, INC. (US) 2025-09-09 — — US disclosed
WO-2025111453-A1 SPS MITIGATION DAY ZERO DIAGNOSTICS, INC. (US) 2025-05-30 — — WO disclosed
CN-113474465-B Improved method for preparing clinical samples for nucleic acid amplification 零日诊断有限公司 2025-04-22 — — CN disclosed
US-20230416845-A1 UNIVERSAL PRIMERS FOR RAPID BACTERIAL GENOME DETECTION DAY ZERO DIAGNOSTICS, INC. (US) 2023-12-28 — — US disclosed
WO-2022164968-A1 METHODS FOR ENRICHING MICROORGANISMS FROM LOW ABUNDANCE CLINICAL SAMPLES FOR DNA SEQUENCING DAY ZERO DIAGNOSTICS, INC. (US) 2022-08-04 — — WO disclosed
WO-2022115318-A1 UNIVERSAL PRIMERS FOR RAPID BACTERIAL GENOME DETECTION DAY ZERO DIAGNOSTICS, INC. (US) 2022-06-02 — — WO disclosed
US-20220127660-A1 AN IMPROVED METHOD OF PREPARING CLINICAL SAMPLES FOR NUCLEIC ACID AMPLIFICATION DAY ZERO DIAGNOSTICS, INC. (US) 2022-04-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260043803-A1 MEANS FOR DETECTING SCHISTOSOMA INFECTION CUTA, H1-10, H1-0 MAPK1 3830/4885LGALS3 1192/4885LGALS8 1639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback